News

Dublin, Ireland-based Alkermes plc announced it will initiate a Phase 1 clinical trial for its drug candidate ALKS7119 for the treatment of agitation in Alzheimer’s patients. Psychiatric symptoms such as agitation are the main cause of morbidity in Alzheimer’s patients and also a major burden among caregivers. There are currently no…

A National Football League broadcaster and former NFL player is urging Americans to “Huddle Up for New Alzheimer’s Treatments” by participating in clinical trials testing new drugs that may potentially treat the degenerative brain disease. The new educational and awareness-raising campaign teams Solomon Wilcots with Axovant Sciences, Ltd., and patient advocacy groups in…

A collaboration between researchers at the Institute for EthnoMedicine and the University of Miami Brain Endowment Bank revealed that chronic exposure to an environmental toxin has the potential to increase the risk for neurodegenerative illnesses such as Alzheimer’s disease. The research paper, “Dietary exposure to an environmental toxin triggers…

Buck Institute and UCLA researchers have discovered a new role for a specific genetic form (allele) of a certain gene, which might explain its status as the most important genetic risk factor for the development of Alzheimer’s disease. The research paper, “Direct Transcriptional Effects of Apolipoprotein E,” was published in…

Lack of sleep on a regular basis or waking up several times during the night may be harmful to the brain and increase the risk of developing Alzheimer’s disease, according to recent evidence. Patients with Alzheimer’s disease tend to sleep poorly and stay awake more often at night. However, researchers have…

PsychoGenics Inc. and the Alzheimer’s Drug Discovery Foundation (ADDF) announced a collaboration that opens PsychoGenics’ Alzheimer’s animal models and investigational services to recipients of ADDF grants who are working in preclinical Alzheimer’s drug discovery programs. Through the collabortion, PsychoGenics will offer its products and services to ADDF-funded biotechnology companies on “extremely favorable…

Neuralstem Inc. researchers have released the preclinical results of a human stem cell line with the potential to treat Alzheimer’s disease patients. The research paper, “Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer’s Disease,” was published in the journal Stem Cells Translational Medicine. Neuralstem’s…

Evotec AG has reached an important milestone concerning its TargetAD partnership with Janssen Pharmaceuticals for the transition of a product into further drug discovery process. Even though the announcement was made this year, the milestone was reached in 2015. Evotec’s TargetAD database is a customized system to provide unique information on the connection between molecular…

Austin-based Alzheimer’s Association Capital of Texas Chapter (known as Alzheimer’s Texas) announced that the organization has separated from the national organization, based in Chicago. The organization, a leader in Alzheimer’s care, education, and support in Central Texas, and the state’s pre-eminent force for new funding for Alzheimer’s disease and dementia research, says that the…

Anavex Life Sciences Corp. reported that a positive dose-response relationship has been observed in its ongoing Phase 2a clinical trial of ANAVEX 2-73 as a potential treatment for mild-to-moderate Alzheimer’s disease (AD). The announcement came as part of a planned, interim study analysis. The ANAVEX 2-73 Phase 2a study is a multicenter trial…